Solvay Doubles Specialty Fluorinated Derivatives Production Capacity in France
News Sep 07, 2012
Solvay announced today it is doubling the production capacity for specialty fluorinated aliphatic derivatives at its plant in Salindres, France, to keep up with the growing demand in strategic markets, such as energy storage, electronics and pharmaceuticals. The Group is investing over EUR 10 million in the plant to double the capacity of the fluorinated aliphatic derivatives production line. The project’s first stage is currently underway and the first additional volumes will be available this month.
The Group decided to double production capacity for triflic acid and triflic anhydride (TA, TAA), as well as for Lithium bis(trifluoromethanesulfonyl)imide (LiTFSI), to meet the rapidly expanding requirements of electronic applications (such as antistatic applications for flat screens, ionic liquids and liquid crystals), the battery market (for automobiles and computers) and the pharmaceuticals market.
“This capacity expansion is strengthening the role of our Salindres plant as a major production site for innovative fluorinated aliphatic derivatives,” commented Alessandro Chiovato, General Manager of the Crop Protection, Health & Electronics business at Solvay's Global Business Unit Rhodia Aroma Performance. “It will bring us in a better position to support the growth of our customers in all regions,” he added.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018